DIFFERENCES IN IMMUNE TRANSCRIPTOMIC PROFILE ARE ASSOCIATED WITH RESPONSE TO AZACITIDINE AND VENETOCLAX IN NEWLY DIAGNOSED UNFIT-FOR-CHEMOTHERAPY ACUTE MYELOID LEUKEMIA PATIENTS

被引：0
|
作者：
Zannoni, L. [1 ]
Forte, D. [1 ]
Sartor, C. [1 ]
Cristiano, G. [1 ]
Nanni, J. [1 ]
Parisi, S. [2 ]
Zingarelli, F. [1 ]
Bandini, L. [1 ]
Testoni, N. [1 ]
Ottaviani, E. [2 ]
Paolini, S. [2 ]
Papayannidis, C. [2 ]
Cavo, M. [1 ,3 ]
Rutella, S. [3 ]
Curti, A. [2 ]
机构：
[1] Univ Bologna, Dipartimento Sci Med Chirurg, Bologna, Italy
[2] Univ Bologna, Ist Ematol Seragnoli, IRCCS Azienda Osped, Bologna, Italy
[3] Nottingham Trent Univ, John Geest Canc Res Ctr, Nottingham, England
来源：
HAEMATOLOGICA | 2024年 / 109卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
P033
引用
收藏
页码：74 / 75
页数：2
相关论文
共 50 条
  • [41] Venetoclax combinations induce high response rates in newly diagnosed acute myeloid leukemia patients ineligible for intensive chemotherapy in routine practice
    Apel, Arie
    Moshe, Yakir
    Ofran, Yishai
    Gural, Alexander
    Wolach, Ofir
    Ganzel, Chezi
    Canaani, Jonathan
    Zektser, Miri
    Duek, Adrian
    Stemer, Galia
    Hellman, Ilana
    Basood, May
    Frisch, Avraham
    Leibovitch, Chiya
    Koren-Michowitz, Maya
    AMERICAN JOURNAL OF HEMATOLOGY, 2021, 96 (07) : 790 - 795
  • [42] Ten-day decitabine as initial therapy for newly diagnosed patients with acute myeloid leukemia unfit for intensive chemotherapy
    Bhatnagar, Bhavana
    Duong, Vu H.
    Gourdin, Theodore S.
    Tidwell, Michael L.
    Chen, Ching
    Ning, Yi
    Emadi, Ashkan
    Sausville, Edward A.
    Baer, Maria R.
    LEUKEMIA & LYMPHOMA, 2014, 55 (07) : 1533 - 1537
  • [43] Venetoclax plus azacitidine in Japanese patients with untreated acute myeloid leukemia ineligible for intensive chemotherapy
    Yamamoto, Kazuhito
    Shinagawa, Atsushi
    DiNardo, Courtney D.
    Pratz, Keith W.
    Ishizawa, Kenichi
    Miyamoto, Toshihiro
    Komatsu, Norio
    Nakashima, Yasuhiro
    Yoshida, Chikashi
    Fukuhara, Noriko
    Usuki, Kensuke
    Yamauchi, Takahiro
    Asada, Noboru
    Asou, Norio
    Choi, Ilseung
    Miyazaki, Yasushi
    Honda, Hideyuki
    Okubo, Sumiko
    Kurokawa, Misaki
    Zhou, Ying
    Zha, Jiuhong
    Potluri, Jalaja
    Matsumura, Itaru
    JAPANESE JOURNAL OF CLINICAL ONCOLOGY, 2022, 52 (01) : 29 - 38
  • [44] Clinical experience with venetoclax in patients with newly diagnosed, relapsed, or refractory acute myeloid leukemia
    Maximilian Fleischmann
    Sebastian Scholl
    Jochen J. Frietsch
    Inken Hilgendorf
    Karin Schrenk
    Jakob Hammersen
    Florian Prims
    Christian Thiede
    Andreas Hochhaus
    Ulf Schnetzke
    Journal of Cancer Research and Clinical Oncology, 2022, 148 : 3191 - 3202
  • [45] Efficacy of hypomethylating agents and Venetoclax in unfit patients with acute myeloid leukemia
    Rieger, M.
    Manz, M. G.
    Muller, R.
    Theocharides, A. P. A.
    Schwotzer, R.
    SWISS MEDICAL WEEKLY, 2020, : 17S - 17S
  • [46] Clinical experience with venetoclax in patients with newly diagnosed, relapsed, or refractory acute myeloid leukemia
    Fleischmann, Maximilian
    Scholl, Sebastian
    Frietsch, Jochen J.
    Hilgendorf, Inken
    Schrenk, Karin
    Hammersen, Jakob
    Prims, Florian
    Thiede, Christian
    Hochhaus, Andreas
    Schnetzke, Ulf
    JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, 2022, 148 (11) : 3191 - 3202
  • [47] Reduced duration and dosage of venetoclax is efficient in newly diagnosed patients with acute myeloid leukemia
    Cui, Jingying
    Chen, Xuexing
    Li, Chunfang
    Yan, Qiong
    Yuan, Guolin
    HEMATOLOGY, 2024, 29 (01)
  • [48] Treatment Response and Impact Factor of Venetoclax Based Regimens in the Frontline Treatment of Newly Diagnosed Unfit Acute Myeloid Leukemia in the Real World of China
    Yu, Guopan
    Yin, Zhao
    Xu, Dan
    Jiang, Xuejie
    Ye, Jieyu
    Zhang, Yu
    BLOOD, 2022, 140 : 11740 - 11740
  • [49] Homoharringtonine Combining with Azacitidine and Venetoclax (HAV) As First-Line Induction Therapy for Newly Diagnosed Adult Acute Myeloid Leukemia Patients
    Lu, Wenyi
    Chen, Xiangli
    Zang, Yuzhu
    Zhu, Zunmin
    Zhang, Wenhui
    Hai, Yanliang
    Chen, Yuqing
    Jiang, Li
    Xing, Yanyan
    Liu, Yuanbo
    Shi, Jie
    Gao, Zhenxing
    BLOOD, 2024, 144 : 6037 - 6037
  • [50] Outcomes and Survival in Newly Diagnosed, Older, Acute Myeloid Leukemia Patients from the Beat AML Master Trial in the Venetoclax/Azacitidine Age
    Borate, Uma
    Huang, Ying
    Li Welkie, Rina
    Swords, Ronan T.
    Traer, Elie
    Stein, Eytan M.
    Lin, Tara L.
    Madanat, Yazan F.
    Patel, Prapti A.
    Collins, Robert H.
    Baer, Maria R.
    Duong, Vu H.
    Blum, William
    Arellano, Martha L.
    Stock, Wendy
    Odenike, Olatoyosi
    Redner, Robert L.
    Kovacsovics, Tibor J.
    Deininger, Michael W.
    Zeidner, Joshua F.
    Olin, Rebecca
    Smith, Catherine C.
    Foran, James M.
    Schiller, Gary J.
    Curran, Emily K.
    Koenig, Kristin L.
    Heerema, Nyla A.
    Chen, Timothy
    Martycz, Molly
    Stefanos, Mona
    Marcus, Sonja Gullen
    Druker, Brian J.
    Levine, Ross L.
    Burd, Amy
    Rossenber, Leohard
    Yocum, Ashley Owen
    Mims, Alice
    Byrd, John C.
    BLOOD, 2024, 144 : 4324 - 4326
12345